ES2175155T3 - Cetoacidos aromaticos y sus derivados como inhibidores de las metaloproteinasas matriciales. - Google Patents

Cetoacidos aromaticos y sus derivados como inhibidores de las metaloproteinasas matriciales.

Info

Publication number
ES2175155T3
ES2175155T3 ES96940614T ES96940614T ES2175155T3 ES 2175155 T3 ES2175155 T3 ES 2175155T3 ES 96940614 T ES96940614 T ES 96940614T ES 96940614 T ES96940614 T ES 96940614T ES 2175155 T3 ES2175155 T3 ES 2175155T3
Authority
ES
Spain
Prior art keywords
inhibitors
aromatic
derivatives
matral
cetoacidos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940614T
Other languages
English (en)
Inventor
Donald Hupe
Linda Lea Johnson
Daniel Fred Ortwine
Claude Forsey Purchase Jr
Andrew David White
Qi-Zhuang Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2175155T3 publication Critical patent/ES2175155T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS CETOACIDOS AROMATICOS DE FORMULA (I) Y A SUS DERIVADOS, ASI COMO A METODOS DE PREPARACION Y A COMPOSICIONES FARMACEUTICAS DE LOS MISMOS, QUE SON UTILES COMO INHIBIDORES DE LAS METALOPROTEINASAS DE LA MATRIZ, ESPECIALMENTE GELATINASA A (GELATINASA DE 72 KD) Y ESTROMELISINA1 Y PARA EL TRATAMIENTO DE LA ESCLEROSIS MULTIPLE, RUPTURA DE PLACAS ARTERIOSCLEROTICAS, ANEURISMA AORTICO, FALLO CARDIACO, RESTENOSIS, ENFERMEDAD PERIODONTAL, ULCERACION CORNEAL, TRATAMIENTO DE QUEMADURAS, ULCERAS DECUBITALES, CICATRIZACION DE HERIDAS, CANCER, ARTRITIS U OTRAS ALTERACIONES AUTOINMUNES O INFLAMATORIAS, DEPENDIENTES DE LA INVASION TISULAR DE LOS LEUCOCITOS. AR, Y, W, R 1 -R 4 SON TAL Y COMO SE LOS DEFINE EN LA DESCRIPCION.
ES96940614T 1995-12-22 1996-11-27 Cetoacidos aromaticos y sus derivados como inhibidores de las metaloproteinasas matriciales. Expired - Lifetime ES2175155T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US948995P 1995-12-22 1995-12-22

Publications (1)

Publication Number Publication Date
ES2175155T3 true ES2175155T3 (es) 2002-11-16

Family

ID=21737977

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940614T Expired - Lifetime ES2175155T3 (es) 1995-12-22 1996-11-27 Cetoacidos aromaticos y sus derivados como inhibidores de las metaloproteinasas matriciales.

Country Status (19)

Country Link
US (1) US6008220A (es)
EP (1) EP0876343B1 (es)
JP (1) JP2000502343A (es)
AT (1) ATE214368T1 (es)
AU (1) AU713174C (es)
BG (1) BG63461B1 (es)
BR (1) BR9612188A (es)
CZ (1) CZ287868B6 (es)
DE (1) DE69619865T2 (es)
DK (1) DK0876343T3 (es)
ES (1) ES2175155T3 (es)
HU (1) HU222986B1 (es)
NO (1) NO309470B1 (es)
NZ (1) NZ323329A (es)
PL (1) PL327494A1 (es)
PT (1) PT876343E (es)
SK (1) SK87598A3 (es)
WO (1) WO1997023459A1 (es)
ZA (1) ZA9610722B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633947T2 (de) * 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US5795985A (en) * 1996-03-05 1998-08-18 Ciba Specialty Chemicals Corporation Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof
ZA974030B (en) 1996-05-15 1998-02-19 Bayer Ag Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids.
TNSN97086A1 (fr) 1996-05-15 2005-03-15 Bayer Corp La substitution des acides derivatives 4-albutyrique comme inhibiteurs de la matrice metalloprotease.
TNSN97085A1 (fr) 1996-05-15 2005-03-15 Bayer Corp Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU737117B2 (en) * 1996-12-17 2001-08-09 Warner-Lambert Company Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
EP1366765A1 (en) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
EP3191453B1 (en) * 2014-09-09 2019-10-23 Bristol-Myers Squibb Company Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3053222B2 (ja) * 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
EP1028716A1 (en) * 1996-12-09 2000-08-23 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
AU737117B2 (en) * 1996-12-17 2001-08-09 Warner-Lambert Company Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing

Also Published As

Publication number Publication date
AU1024997A (en) 1997-07-17
BG102471A (en) 1999-08-31
NO309470B1 (no) 2001-02-05
ZA9610722B (en) 1997-06-27
CZ287868B6 (en) 2001-02-14
PL327494A1 (en) 1998-12-21
ATE214368T1 (de) 2002-03-15
AU713174B2 (en) 1999-11-25
DK0876343T3 (da) 2002-07-01
US6008220A (en) 1999-12-28
JP2000502343A (ja) 2000-02-29
WO1997023459A1 (en) 1997-07-03
EP0876343B1 (en) 2002-03-13
BR9612188A (pt) 1999-07-13
CZ195298A3 (cs) 1998-09-16
SK87598A3 (en) 1999-04-13
NO982840D0 (no) 1998-06-19
MX9803315A (es) 1998-09-30
PT876343E (pt) 2002-08-30
HUP9902079A3 (en) 2000-06-28
NZ323329A (en) 1999-02-25
BG63461B1 (bg) 2002-02-28
EP0876343A1 (en) 1998-11-11
HU222986B1 (hu) 2004-01-28
DE69619865D1 (de) 2002-04-18
NO982840L (no) 1998-06-19
DE69619865T2 (de) 2002-11-07
HUP9902079A2 (hu) 1999-10-28
AU713174C (en) 2002-05-02

Similar Documents

Publication Publication Date Title
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ES2161290T3 (es) Derivados de quinazolina.
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
AR026410A1 (es) ''2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas sustituidas, y las composiciones y metodos farmaceuticos relacionados
ES2123810T3 (es) Heterociclos utiles como antagonistas de neuroquinina.
PA8518701A1 (es) Derivados de tiofeno utiles como agentes anticancerosos
MX9300786A (es) Compuestos hipolipidaemicos.
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
ECSP045497A (es) "difenilazetidinonas sustituidas con grupos acidos, metodo para su producción, medicamentos que comprenden dichos compuestos y su uso"
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ES2054844T3 (es) Nuevos esteroides que comprenden un ciclo espiranico con 3, 4 o 6 eslabones en posicion 17, su procedimiento, y productos intermedios de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
ES2121597T3 (es) Derivados de bencenosulfonamida para el tratamiento de la inestabilidad de la vejiga.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
MX9601635A (es) Derivados de antraciclina.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2153457T3 (es) Amino-alquil-benzoxazolinonas y benzotiazolinonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 876343

Country of ref document: ES